Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of OncologyAccesswire • Thursday
Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000Accesswire • Monday
Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35MAccesswire • 11/15/24
Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%Accesswire • 11/01/24
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary BrandsAccesswire • 09/25/24
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit MarginsAccesswire • 09/23/24
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection KitsAccesswire • 09/23/24
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 BillionAccesswire • 09/19/24
Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin SegmentsAccesswire • 09/18/24
Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and QatarAccesswire • 09/16/24
Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.PRNewsWire • 09/16/24
Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection KitsAccesswire • 08/21/24
Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs.Accesswire • 08/20/24
Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross ProfitAccesswire • 08/20/24
Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ MarketAccesswire • 08/08/24
Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per ShareAccesswire • 08/06/24
Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS ScotlandAccesswire • 07/25/24
Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in QatarAccesswire • 07/25/24
Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full CapacityAccesswire • 07/24/24
Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million UnitsAccesswire • 07/18/24
Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global MarketAccesswire • 07/10/24
Cosmos Health's Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units AnnuallyAccesswire • 07/09/24
